Innovent Highlights Obesity Pipeline at ADA 2026
SAN FRANCISCO and SUZHOU, China, May 12, 2026 Innovent Biologics announced that it will present multiple clinical and preclinical...
oral GLP-1
Advertisement
Eli Lilly Strengthens GLP-1 Leadership With New Foundayo Trial Results
INDIANAPOLIS, May 12, 2026 Eli Lilly and Company has reported positive results from two major late-phase obesity trials showing...
FDA Clears Ascletis ASC30 Phase II Diabetes Study
HONG KONG, Jan. 5, 2026 — Ascletis Pharma Inc. announced that it has received Investigational New Drug (IND) clearance...
Lilly’s Oral GLP-1 Orforglipron Sustains Weight Loss in Phase 3 Trial
Indianapolis, December 18, 2025 — Eli Lilly and Company announced positive topline results from its first-of-its-kind Phase 3 ATTAIN-MAINTAIN...
Lilly’s Oral GLP-1 Orforglipron Delivers Strong Phase 3 Results in Type 2 Diabetes
INDIANAPOLIS, Oct. 15, 2025 — Eli Lilly and Company (NYSE: LLY) announced positive topline results from two pivotal Phase...
Advertisement
